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ABSTRACT 
 
Chronic low-grade inflammation present in hypertrophic obesity has the 
ability to cause remodeling of the adipose tissue due to the increased presence 
of macrophages and pro-inflammatory cytokines. Transforming Growth Factor-β 
(TGF- β) is a cytokine released from macrophages that is increased in obesity 
and plays a major role in extracellular matrix (ECM) remodeling of tissues. 
Lipocalin 2 (Lcn2), a cytokine expressed in adipose tissue, is related to 
inflammation and ECM remodeling. Due to the qualities that both adipokines 
possess the role in extracellular matrix remodeling and inflammation, we looked 
into the TGF- β effect on the regulation of ECM and inflammatory cytokines in 
Lcn2 deficient adipocytes to acquire more information about the function of Lcn2 
under inflammatory stimuli and the association with metabolic diseases. 
Therefore, we performed experiments to address how Lcn2 knock out (KO) 
influences the response of adipocytes to TGF- β in the production of pro-
inflammatory and anti-inflammatory cytokines and ECM proteins. Our results 
demonstrate that TGF- β down-regulates Lcn2 expression at both the mRNA and 
protein levels in inguinal adipocytes. Lcn2 KO adipocytes have lower levels of 
TGF- β expression, but normal levels of p70S6K phosphorylation and normal 
response to TGF- β stimulation in mammalian target of rapamycin complex 1 
(mTORC1) signaling activation. However, the inhibitory effect of rapamycin on 
TGF- β expression is attenuated in Lcn2 KO adipocytes. Moreover, Lcn2 KO 
impairs the rapamycin potentiation of TGF- β effect on the expression of ECM 
proteins, but shows little effect on dysregulation of cytokines. 
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I. Obesity and metabolic diseases 
a. Prevalence of obesity   
Overweight and obesity are a growing worldwide epidemic linked to 
poor health outcomes and increased risk for other chronic diseases. 
Defined as excess body fat causing altered health status and 
characterized by low-grade, systemic inflammation, overweight and 
obesity pose threat to normal metabolic function (1). A body mass index 
(BMI) of 25 kg/m2 or greater is considered overweight, whereas a BMI of 
30 kg/m2 or greater classifies an individual as obese. According to the 
World Health Organization (WHO), 68% of Americans are either 
overweight or obese; 35.1% of adults in the United States and 13% (600 
million) of adults worldwide over 20 years of age are obese. This disease 
also affects approximately 18% of children ages 6-19 in the United States 
and 42 million children under the age of 5 worldwide, increasing disease 
risk for the upcoming generations. Causes of obesity are commonly 
associated with increased intake versus expenditure or caloric surplus, 
genetics, metabolic stress, aging, and medications, although obesity is 
considered a preventable disease (2,3).  
Obesity, often associated with excess adipose storage in the visceral 
depot, is highly comorbid with chronic diseases such as type II diabetes 
mellitus (DMII), insulin resistance (IR), cancers, non-alcoholic fatty liver 
disease, metabolic disease, sleep apnea, atherosclerosis, and heart 
disease and its related complications such as dyslipidemia, ischemia, 
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hypertension, and death (4,5,6). Obesity is also correlated with a shorter life 
span and higher economic consequences due to healthcare costs (7).  
 
b. Mechanisms for the development of obesity 
Energy release from the adipose tissue comes from the 
dispersion of fatty acids into circulation. The fatty acids present 
within the adipocyte are generated by the breakdown of 
triacylglycerols, the primary storage form of fat within the adipocyte, 
and released when the primary fuel, glucose, is not readily 
available (8,9). Each lipid droplet is composed of a phospholipid 
monolayer that surrounds a lipid core. In a fed state, surplus energy 
is stored in the form of triacylglycerol in a lipid droplet within the 
adipocyte; this core is protected from lipases by perilipin 1, which is 
released upon feeding. In a fasting state, triacylglycerols are 
hydrolyzed by hormone-sensitive lipase and adipose triglyceride 
lipase to release fatty acids for energy (9).  The imbalance created 
between energy intake and expenditure is the major contributor to 
the accumulation of excess fat mass, leading to the development of 
obesity.  
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II. Adipose tissue in obesity and diabetes 
a. White adipose tissue (WAT) 
WAT serves as a site for energy storage in the form of triacylglycerols 
and as an endocrine organ, working to regulate energy, maintain weight 
homeostasis, control inflammatory response, and to regulate the action of 
insulin. Adipose tissue also has mechanical function to protect the heart 
and other major organs from damage by serving as insulation or cushion 
(2).  
The WAT is composed of mature adipocytes and the stromal-vascular 
component consisting of immune cells– such as T cells and macrophages, 
blood vessels, pre-adipocytes, extracellular matrix (ECM), and fibroblasts. 
The fibroblasts support and synthesize the collagen, which makes up the 
ECM (2).  
All of the functions of adipose tissue are depot dependent. In humans, 
adipose tissue can be found in two major depots, the subcutaneous and 
visceral adipose tissue, but can also be located intramuscularly (4,8,10). 
Visceral adipose tissue is known to have higher turnover rates than 
subcutaneous adipose tissue (11). Studies indicate that fat distribution can 
be controlled by multiple factors, one of the major factors being sex, due 
to differences in hormone secretion; men tend to accumulate fat viscerally 
and women, subcutaneously. Age and physical activity level are also 
linked to depot-specific adiposity, which increased age and decreased 
activity levels contribute to visceral adiposity, respectively (12).  
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Subcutaneous adipose tissue development typically occurs before visceral 
adipose tissue, starting in the second trimester in utero (13).   
The subcutaneous depot is associated with fat storage beneath the 
skin, whereas the visceral depot is located around the organs and intra-
abdominally. These depots are differential in terms of their adipogenic 
capability, secretory function, and inflammatory response (10). Visceral 
adipose tissue is often related to a higher lipogenic activity, whereas 
subcutaneous depots have a lower lipid turnover (11,12).  
Studies support evidence that increased visceral adipose tissue is 
linked to higher morbidity rates for type II diabetes mellitus and 
cardiovascular disease due to its direct relationship with release of free 
fatty acids (FFA) into portal circulation to the liver (4,8,12). The increase in 
FFA increases lipogenesis and gluconeogenesis in the liver, causing 
insulin resistance and exacerbating the affects of increased adiposity such 
as glucose intolerance, hypertension, and atherosclerosis (12).  
Mice also have differing depots that support different metabolic 
functions. Mice have four abdominal adipose depots, perigonadal (in male 
mice), perirenal, mesenteric, and omental depots. The two superficial 
depots are the inguinal and subscapular (brown) depots. These depots 
also show regional differences in many attributes such as cell 
differentiation, gene expression, protein abundance, and growth, causing 
overall differences in function (10). Research found that oxidative 
metabolism is higher in specific depots in mice as it is in human adipose 
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tissue; the female periovarian depot is higher in oxidative metabolism than 
the inguinal adipose tissue, but the interspacular brown adipose is 
significantly higher than both of the mentioned depots (11).   
 
b. Functions of WAT 
i. Lipid storage  
The primary role of WAT is energy storage. There are two different 
forms of storage in the functional adipocyte, hypertrophy, which 
describes an increase in cell size, versus hyperplasia, which is an 
increase in number of adipocytes. Adipocytes have a rapid response to 
nutrient balance—in a surplus, the adipocyte will increase in size, in a 
deficit, the adipocyte with decrease in size to maintain energy 
homeostasis (2).   
Both forms of storage, hyperplasia and hypertrophy, increase the 
total adipose tissue, which increases the event of apoptosis, 
dysregulation of fatty acid homeostasis, hypoxia, and cytokine 
secretion; hypertrophy is more often related to increased inflammation 
and hypoxia due to the changes in metabolic function and secretion 
within the cells (4,14). Additionally, hypertrophy poses a higher risk 
because it is more prevalent in obesity that hyperplasia (14). Research 
indicates that mice fed a chronic high-fat diet have larger fat pads that 
have fewer adipocytes present, suggesting high-fat diets aid in 
reducing adipogenesis and promote hypertrophy (6).  
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ii. Metabolic function and secretion  
Another major function of WAT is secretion of adipokines and 
cytokines (5). A normal, metabolically stable adipose tissue displays 
characteristics of proper vascularization and normal secretion of 
adipokines and cytokines to aid in immune regulation, energy 
metabolism, and insulin sensitivity regulation. Adipocyte dysfunction 
associated with obesity is present when cells are hypertrophic, 
hypoxic, and/or have increased inflammation (4).  
It is in fully dysfunctional adipose tissue where inflammation is 
present, increased secretion of pro-inflammatory cytokines, recruitment 
of macrophages, and T-helper cells occurs. With any dysfunction 
present, pro-inflammatory cytokines are introduced to the tissue, and 
cells become hypoxic due to decreased access to vascularization; as 
the adipocyte increase in size, the areas of the cell lacking access to 
the nutrients delivered by the vasculature, especially oxygen, become 
dysfunctional and potentially become necrotic exacerbated by 
macrophage infiltration (4).  
Because of lack of access to vasculature and increased 
inflammation, hypertrophy often contributes to a localized hypoxia 
versus hyperplasia, which is often coined “metabolically healthy” 
adipose expansion (4). Wernstedt Asterholm et al define this 
metabolically healthy adipose tissue by association with appropriate 
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angiogenesis, vascular remodeling, and extracellular matrix 
remodeling (6). There is dysfunction present in hypertrophy because it 
often includes an increase in pro-inflammatory adipokines, especially 
matrix metallopeptidase 9 (MMP9), Interleukin 6 (IL-6), and leptin (14).  
 
1. Inflammation and ECM remodeling  
Chronic low-grade inflammation present in hypertrophic obesity has 
the ability to cause remodeling of the adipose tissue due to the 
increased presence of macrophages and released cytokines. 
Dysfunction of the extracellular matrix is a result of the macrophage 
infiltration, adipocyte hypertrophy, and increased ECM remodeling (4).  
To some extent, ECM remodeling is necessary to maintain adipose 
tissue health and the average fat cell turns over every 8-12 years, but 
fibrosis can occur as a result of remodeling in the adipose tissue. 
Therefore, remodeling of the adipose tissue is a continuous process, 
but the consequences of excess remodeling that occurs during obesity 
are of note (14). In the obese state, remodeling occurs more often and 
rapidly, excelling the natural progressive progress and decreasing the 
efficiency of adipocyte function and disrupting metabolic homeostasis 
of the adipose tissue (6,14).  
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2. Macrophage infiltration and inflammation 
In studies conducted by Toubal et al, the pathway controlling 
obesity-related inflammation in human adipocytes through 
transcriptional reprogramming was examined. They found that the 
SMRT-GPS2 copressor complex suppresses the pathway that controls 
the transcription of monocyte chemoattractant protein-1 (MCP-1) and 
IL-6 that contributes to macrophage infiltration and inflammatory 
response (15). Other studies have confirmed that nuclear factor kappa-
light-chain-enhancer of activated B cells (NFκB) pathway works in 
opposition of the SMRT-GPS2 compressor complex by upregulating 
inflammatory cytokine, chemokine, and adipokine expression (16).  
Macrophages are significant contributors to the inflammatory 
response present in obesity (17,18). They are promoted by free fatty 
acids and chemokines, such as MCP-1, which are upregulated in 
inflammation. The mobilization of macrophages from the bone marrow 
initiates the remodeling process of the adipocyte (2,14,19). Research 
shows that Infiltration of macrophages is more evident in visceral WAT 
in an obese adult, but the subcutaneous tissue showed higher 
production of collagens and remodeling-related secretory protein. 
MCP-1, which is highly expressed in the stromal-vascular (SV) fraction 
of the adipose tissue, and IL-6 are both 2.4 fold and 4.1 fold, 
respectively, higher in the visceral adipose tissue than in subcutaneous 
adipose tissue when a pro-inflammatory state is present (19). Other 
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research involving hypertrophic cells by Dalmas et al indicates that 
when adipocytes become hypertrophic, they are more likely to produce 
cytokines IL-6, Interleukin-8 (IL-8), and markers of inflammation, such 
as MCP-1. Their lean model equivalent secreted anti-inflammatory 
cytokines, such as Interleukin-13 (IL-13) and Interleukin-10 (IL-10), 
adiponectin, and promoted the immunosuppressive, alternative 
macrophage (20).  
Pro-inflammatory cytokines promote macrophage infiltration and 
activation (19), causing macrophages to aggregate and form crown-like 
structures that surround the adipocyte. This is a hallmark of chronic 
inflammation and can cause remodeling in adipose tissue. The 
macrophage will attach to the adipocyte, and through phagocytosis, 
remove the lipid droplet causing adipocyte death and further 
macrophage infiltration (14).  
Previous research indicates macrophages can present an 
inflammatory-controlled response in the pro-inflammatory classic form, 
as M1 marker, or in an activated, immunosuppressive form, M2 
marker.  Obesity is highly correlated with the presence of the M1 
macrophage, where lean subjects often present with increased M2 
macrophages. This increase of M1 macrophages occurs due to the 
recruitment of resident macrophages that are responsive to the 
environment and contribute to the polarization of the M2 marker to M1 
marker (17).  
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III. Transforming Growth Factor β 
a. The TGF- β signaling pathway and metabolic functions 
Transforming Growth Factor-β (TGF- β) is a cytokine 
released from macrophages that is increased in obesity. The 
regulatory action of TGF- β is robust, as it includes tissue growth 
and development, immunity, cell differentiation, production of the 
ECM, and cell cycle control (21,22); its actions are highly dependent 
on cell type and the context of stimulation. TGF- β activates both 
protein kinases mammalian target of rapamycin complex 1 
(mTORC1) and mTOR complex 2 (mTORC2) rapidly, both working 
in conjunction to support the mechanistic action of TGF- β (22).   
The mTOR signaling pathway activation by TGF- β is 
controlled by the activation of cyclooxygenase-2 (COX-2), a 
bifunctional, rate-limiting enzyme that converts arachidonic acid to 
prostanoids. Extensive numbers of studies have shown that 
multiple cell-dependent signaling pathways regulate COX-2, which 
is induced by cytokines, tumor promoters, and growth factors, and 
TGF- β has been shown to induce the expression of this enzyme 
(23,24).  
The pathway that is activated when TGF- β initiates the 
phosphorylation of mothers against decapentaplegic homolog 2 
(Smad2) and Smad3, which bind and complex with Smad4. This 
complex is then recognized by the Smad-binding elements in the 
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nucleus and regulates gene expression in conjunction with other 
transcription factors (25). This increase in gene expression of Smad 
activates the phosphatidylinositol 3-kinase (PI3K), Protein Kinase B 
(AKT), and mTOR (PI3K/AKT/mTOR) signaling pathway by 
increasing COX-2 and Prostaglandin E2 (PGE2) activation (22,24,25). 
PGE2 then activates a G-coupled protein increasing 
phosphorylation of AKT, mTOR, and its downstream targets such 
as S6 Kinase (S6K) (25). Figure 1 shows the proposed pathway of 
TGF-β activation in adipocytes adapted from Vo et al. 
Increased mTORC1 signaling is associated with “pro-growth” 
signals including: extracellular matrix remodeling, a decrease in 
anti-inflammatory cytokines, and increase in pro-inflammatory 
cytokines. mTORC1 activation, however, is mediated by multiple 
factors, thus challenging the direct effect of TGF- β on this pathway 
(25). Research conducted by Martin et al found that phosphorylation 
of 4E-BP1/2, which influences the translation of proteins for 
cytokines. Activation of 4E-BP1/2 resulted in increases in anti-
inflammatory IL-10 and decreases in pro-inflammatory Interleukin-
12 (IL-12) (26). mTORC2 is associated with an increased 
phosphorylation of serine 473 of AKT (22,26), which is upstream of 
mTORC1, and has displayed characteristics of actin re-organization 
(26).  
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b. TGF- β function in adipocyte differentiation 
A study conducted by Bortell et al determined the effect on 
adipocyte differentiation when treated with 100 pM TGF- β1 
and showed the effects of cell proliferation and development 
on the 3T3-L1 pre-adipocytes. After treatment for 36-40 
hours, the differentiation of the pre-adipocytes was blocked. 
The messenger Ribonucleic Acid (mRNA) expression and 
protein levels of collagen I and fibronectin were decreased, 
but not causing any physiological changes until later in 
differentiation, causing a switch in adipogenesis  (27).  
TGF- β KO mice, as discovered by Kulkarni et al, are 
born the same as their wild type (WT) littermates 
phenotypically, but begin to rapidly waste, losing half of their 
body weight by 2 weeks of age. They also have early onset 
of death between three and five weeks of age due to 
cardiopulmonary complications, triggered by inflammation 
induced by overwhelming macrophage infiltration (28). This 
suggests that TGF- β does indeed have a robust function 
that is cell-dependent.  
 
c.  TGF- β and cancer  
Studies have linked TGF- β to tumorigenesis and the pro-
growth response due to high levels of COX-2 expressed in the 
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cancer cell. In prostate cancer, TGF- β’s effect on cell proliferation, 
migration, and invasion were studied, which demonstrated and 
confirmed the effects of TGF- β on AKT phosphorylation and COX-
2 expression. TGF- β acts as a tumor suppressor in early stages of 
the cancer by inducing apoptosis, but in later stages, TGF- β 
demonstrates its pro-growth activity and becomes a tumor promoter 
(24).   
Other research has found that suppression of TGF- β 
signaling and the use of therapeutic rapamycin, an inhibitor of cell 
proliferation, restored cancer cell apoptosis versus simply using 
rapamycin to block mTOR signaling. It is pivotal to suppress the 
apoptotic signals in early stages of cancer progression as a first line 
of defense (29). B. Law et al found similar results in both human and 
rodent cells showing rapamycin potentiates growth arrest that is 
induced by TGF- β in G1 non-transformed epithelial cells and 
restores growth arrest in oncogene-transformed epithelial cells. 
They also found that TGF- β works in response to rapamycin, but 
the effects of rapamycin, especially on phosphorylation of S6K, are 
not changed by the presence of TGF- β (30).  
 
d.  TGF- β in obesity and other metabolic diseases 
In a positively correlative manner with BMI, studies show 
that expressed levels of TGF- β are higher in obese subjects than 
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in their lean counterparts. TGF- β is a major inducer of plasminogen 
activator inhibitor 1 (PAI-1), which is a marker for subjects that have 
undergone a myocardial infarction or angina (31), signifying its 
relationship to heart disease.  
Pfeiffer et al researched the relationship between circulating 
TGF- β levels and the incidence of type II diabetes mellitus, finding 
that plasma levels of TGF- β were positively correlated with 
glycosylated hemoglobin, which is a marker for DMII. They also 
found that the incidence of retinopathy and neuropathy was more 
prevalent in the subjects with higher plasma TGF- β (32). This 
indicated that there is an association between TGF- β and the 
growing complications presenting with obesity.  
 
e. Role of TGF- β in fibrosis 
TGF- β is strongly associated with synthesis of ECM protein 
in most fibrogenic cells and is an important regulator of the fibrotic 
response (21,33). It aids in controlling ECM proteins by stimulating 
production of the fibrogenic agents, such as collagen and 
fibronectin, and inhibiting degradation of ECM proteins (14).  
Studies have shown that TGF- β mediates the fibrotic 
process, but under specific conditions, TGF- β can lead to 
dysfunction and cause alterations in fibrosis (25). Lamouille et al 
found that mTORC2 is related to cell invasion, which accompanies 
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degradation of the extracellular matrix, due to its association with 
upregulating MMP9 (22).  
Fibrosis can occur over time when there is dysregulation in 
the homeostasis of the profibrotic and antifobrotic cytokines and 
proteins. Excessive scarring of tissues due to the production, 
deposition and contraction of an abundance of extracellular matrix 
proteins define fibrosis (21). The importance of the ECM is that it 
plays a primary role in mechanic support for tissues and when 
dysregulated, can cause necrosis, leaving the inert lipid droplet, 
stimulating lipodystrophy (14). As mentioned previously with regards 
to inflammation, the excess of these inert lipid droplets exacerbate 
insulin resistance and inflammation within the cell.  
 
IV. Lipocalin 2  
a. Lipocalin 2 background  
Lipocalin 2 (Lcn2), also known as neutrophil gelatinase-
associated lipocalin (NAGL), is a 25 kDa adipose-derived cytokine 
expressed in adipose tissue, belonging to a lipocalin subfamily that 
binds retinoids, fatty acids, and steroids (1,2,5,34,3536-38,3,39,40). The 
structure of Lcn2 is similar to that for retinol binding proteins and 
fatty acid binding proteins, and contains a promoter region with 
binding sites for nuclear factor- kB (NFkB), glucocorticoid promoter 
region, and CCAAT/enhancer-binding protein (C/EBP). This 
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suggests that the adipokine may serve in adipose tissue 
remodeling and is influenced by inflammation and metabolic 
conditions which upregulate inflammation or dysfunction (2,5).  
In research conducted by Jun et al, the relationship between 
wild type and Lcn2 KO male and female mice was examined. When 
fed a standard chow diet or high-fat diet, the wild type and Lcn2 KO 
mice showed no changes in phenotype (5). Contradicting their 
findings, Guo et al found that when fed a high-fat diet, Lcn2 KO 
mice are more obese than the wild type mice raised under the 
same conditions (35). Interestingly, studies conducted by I. Law et al 
showed that Lcn2 KO mice were significantly leaner than the WT 
mice under high fat diet fed conditions (40).  
 
  b. Lcn2 and inflammation 
It was discovered that Lcn2 is secreted from adipocytes in a 
depot-selective and age-dependent manner. The presence of Lcn2 
is upregulated in obesity, hyperlipidemia, infection, and hypoxia. 
The metabolic changes related to decreased Lcn2 and obesity is 
associated with increased insulin resistance and inflammation (2,3,5). 
The use of thiazolidinedione in obese mice significantly reduces 
circulating Lcn2 levels (39).  
When researching the relationship between Lcn2 and 
macrophage polarization, evidence shows that Lcn2 deficiency 
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supports and increase in pro-inflammatory M1 macrophage 
markers and a decreased expression in the anti-inflammatory M2 
macrophage markers. This suggests that Lcn2 plays a protective 
role against inflammation and macrophage polarization (1).  
Guo, et al researched the effect of Lcn2 on adipogenesis 
and adipose tissue remodeling using Lcn2 knockout (KO) mice. 
The Lcn2 KO mice fed a high-fat diet display characteristics of 
increased adiposity, dyslipidemia, fatty liver disease, and IR (2). 
Lcn2 is significantly upregulated by pro-inflammatory cytokines 
such as tumor necrosis factor α (TNFα), interleukin-1β (IL-1β), and 
Lipopolysaccharide (LPS) in 3T3-L1 cells (2,39).  
Other studies show that Lcn2 expression and secretion is 
not only regulated by cytokines, but also glucose, norepinephrine 
(NE), fatty acids, and insulin, although versus insulin, LPS is a 
more effective stimulant for Lcn2 expression and secretion (3). Lcn2 
is upregulated by these stimulants, but the mechanism as to how 
Lcn2 regulates inflammation is still unclear. 
 
c. Lcn2 and obesity  
With support showing that adipose tissue is a major 
contributor to the synthesis and secretion of adipokines, such as 
Lcn2, that control the inflammatory response, glucose metabolism, 
and action of insulin, there is evidence that obesity alters the 
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normal functions of this organ (39). Research conducted by Zhang 
et al demonstrated that Zucker obese rats that had significantly 
increased mRNA levels of Lcn2 in both the liver and epididymal 
adipose tissue.  
Due to its relationship with obesity and inflammation, Lcn2 
has a suspected role in the remodeling of adipose tissue with 
changes in expression of ECM genes. Previous research in our lab 
found inguinal depots are more responsive to high-fat diet than 
epididymal in KO mice and feeding a high-fat diet led to an increase 
in fat cell size and decrease in number of fat cells present, 
impairing adipogenesis. Wild type mice fed a high-fat diet for 30 
weeks showed an increase in cell count, indicating hyperplasia, 
versus the KO mice, which displayed an increase in the diameter of 
the cells, which would indicate hypertrophy (2).  
Decreased adipogenesis, tissue fibrosis, and hypertrophy 
are all related to insulin resistance caused by obesity-related 
inflammation, due to the alterations in the glucose transporter type 
4 (GLUT4) transporters for carbohydrate (CHO) metabolism and 
increased expression of pro-inflammatory cytokines (2). Human 
studies support these findings in that overweight subjects with type 
II diabetes had higher circulating levels of markers regulating 
inflammation such as TNFα and IL-8, as well as increased mRNA 
expression of diabetes predictors (41).  
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Research shows that there is a positive correlation between 
circulating Lcn2 levels and percentage of body fat percentage, 
blood pressure levels, insulin resistance, and altered lipid panels. 
Song et al researched this by measuring Lcn2 levels in obese mice 
and found positive correlations between these parameters; Wang et 
al found similar results in which circulating Lcn2 levels were 
reflective of increased adiposity, insulin resistance, and triglyceride 
levels (38).   
Other studies have shown that circulating levels of Lcn2 are 
related to obesity in women, but do not serve as a marker for 
insulin resistance (42). In contrast, studies have also found that 
plasma Lcn2 levels do not correlate with markers of obesity or 
metabolic disease. Catalan et al reported that there were no 
differences between the plasma levels of Lcn2 in obese versus lean 
subjects, although there was a reported association between 
obesity and a Lcn2/MMP9 complex (43).  
 
d. Lcn2 and cancer  
Because of the role Lcn2 plays in inflammation and has 
been extensively studied as a tumor-associated protein, its 
connection as a complex with MMP9 is of relevance. Associations 
have been made between increased Lcn2 levels, especially the 
Lcn2/MMP9 complex, and the prevalence of cancer. Koh et al 
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found that in gastric cancer, Lcn2 and MMP9 expression levels 
were upregulated by hepatocyte growth factor (HGF), which 
increased the signaling of the PI3K/AKT/mTOR pathway. Gastric 
tumors were found to have increased Lcn2/MMP9 complex, 
suggesting increased invasion and progression of the tumor cells 
(16). Ruiz-Morales et al also found cancer stage-dependent 
increase in the Lcn2/MMP9 complex in lung adenocarcinoma (34). 
Other studies have confirmed that increased expression of Lcn2 is 
linked to increased incidence of liver (44), esophageal (36), prostate 
(45), colorectal (46), and oral cancers (47).  
 
e. TGF- β and Lcn2 in activation of mTOR signaling  
The role of TGF- β in the activation of mTOR signaling is 
related to its relationship with PGE2. It is known from preliminary 
studies in our lab that the production of PGE2 is increased in Lcn2 
KO adipocytes, suggesting that the presence of Lcn2 may reduce 
the levels of PGE2, thus decreasing the mTOR signaling. TGF- β 
also works to upregulate the pathway involving PGE2, thus 
signaling in the Lcn2 KO mice, in conjunction with TGF- β would 
increase the mTOR signaling versus the wild type mice.  
Other research from our lab shows that with a decreased 
expression of TGF- β in the inguinal adipose depots, there was a 
higher rate of hypertrophy present in the mice overall. The rationale 
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is that the decrease in hypertrophy is compensating for the ability of 
the depots to increase lipid storage capacity, undergoing 
adipogenesis (2).  
In the wild type versus the Lcn2 KO mice, there were 
significant differences in mRNA expression and protein expression 
for extracellular matrix proteins, collagen I and III, fibronectin 1 and 
TGF- β in the epididymal adipose tissue KO mice when fed a high 
fat diet. In the SV fraction of epididymal adipose tissue, the 
opposite effect was found in that the Lcn2 KO mice, both collagen 
III and fibronectin were down-regulated versus their wild type 
equivalents; in inguinal adipose tissue, there were no significant 
alterations in the extracellular matrix genes when comparing the 
wild type and KO models (2).  
 
V. Summary and Objectives  
In summary, obesity causes metabolic distress and dysregulates 
cytokines and adipokines such as TGF- β and Lcn2. TGF- β is a pro-
inflammatory cytokine upregulated in obesity, but its relationship with Lcn2, an 
adipokine that is also positively correlated with obesity is still unclear. Due to the 
qualities that both adipokines possess in extracellular matrix remodeling and 
inflammation, looking into the TGF- β effect in Lcn2 deficient mice may provide 
insight on these processes. Since this relationship has not been studied in 
adipose tissue, it is necessary to acquire more information about the function of 
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Lcn2 under inflammatory stimuli and the association with metabolic diseases and 
its metabolic consequences is needed.  
Our hypothesis is that Lcn2 KO mice will have dysregulated extracellular 
matrix remodeling and altered pro-inflammatory and anti-inflammatory cytokine 
responses versus their wild type counterparts. Therefore, our objectives are to 
determine how Lcn2 is involved in the effect of TGF- β on inflammation and 
extracellular matrix remodeling in inguinal adipocytes and how Lcn2 KO will 
influence pro-inflammatory and anti-inflammatory cytokines and dysregulate 
ECM remodeling.  
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Figure adapted from Vo, et al 
Figure 1. A proposed pathway suggesting TGF- β increases COX-2 and 
PGE2 expression to activate the PI3K/AKT/mTOR signaling pathway in 
adipocytes, thus influencing remodeling of the ECM and dysregulation of 
cytokine expression.  
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CHAPTER 2 
 
 
 
LIPOCALIN 2 DEFICIENCY INFLUENCES TGF-β EFFECT ON 
INFLAMMATION AND EXTRACELLULAR MATRIX REMODELING IN 
INGUINAL ADIPOCYTES 
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I. Introduction  
As the prevalence of overweight and obesity continue to rise 
globally, so does the risk of obesity-related diseases such as type II diabetes 
mellitus (DMII), insulin resistance (IR), cancers, heart disease and death (4,6). 
Obesity is commonly associated with caloric surplus, genetics, metabolic stress, 
aging, and medications, although obesity is considered a preventable disease 
(2,3); the imbalance created between energy intake and expenditure is the major 
contributor to the accumulation of excess fat mass, leading to the development of 
obesity.  
 White adipose tissue (WAT) serves as the main site for energy  
storage and works as an endocrine organ to regulate energy homeostasis, 
inflammatory response, the secretion of adipokines and cytokines, and to control 
the action of insulin. Adipose tissue also has mechanical function to protect major 
organs from damage by serving as insulation. There are two forms of energy 
storage in the functional adipocyte, hypertrophy, which is an increase in cell size, 
versus hyperplasia, which is an increase in number of adipocytes (2,4,14.    
Although both forms of storage, hyperplasia and hypertrophy, increase the 
amount of total adipose tissue, adipocyte hypertrophy is more closely associated 
with increased occurrence of apoptosis, hypoxia, and cytokine secretion as well 
as dysregulation of fatty acid homeostasis (14). Adipocyte dysfunction associated 
with obesity is present when cells are hypertrophic, hypoxic, and/or have 
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increased inflammation due to decreased access to vascularization. Chronic low-
grade inflammation present in hypertrophic obesity has the ability to cause 
remodeling of the adipose tissue due to the increased presence of macrophages 
and pro-inflammatory cytokines. Dysfunction of the extracellular matrix (ECM) is 
a result of the macrophage infiltration, adipocyte hypertrophy, and ECM 
remodeling (4). In obesity, remodeling occurs more frequently and rapidly, 
excelling the natural progressive progress of fibrosis and decreasing the 
efficiency of adipocyte function and metabolic homeostasis of adipose tissue 
(6,14). 
Transforming Growth Factor-β (TGF- β) is a cytokine released from 
macrophages that is increased in obesity and plays a major role in ECM 
remodeling of tissues. The regulatory action of TGF- β includes tissue growth 
and development, immunity, cell differentiation, production of the ECM, and cell 
cycle control (21,22). TGF- β activates both protein kinases mammalian target of 
rapamycin complex 1 (mTORC1) and mTOR complex 2 (mTORC2) rapidly (22) 
by indirectly activating the phosphatidylinositol 3-kinase (PI3K), Protein Kinase B 
(AKT), and mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR) signaling 
pathway (22,24,25).  
Increased mTOR complex 1 (mTORC1) signaling is associated with “pro-
growth” signals including: ECM remodeling, a decrease in anti-inflammatory 
cytokines, and increase in pro-inflammatory cytokines. TGF- β aids in controlling 
ECM proteins by stimulating production of the fibrogenic agents, such as 
collagen and fibronectin, and inhibiting degradation of ECM proteins through 
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activation of mTOR. The ECM plays a primary role in mechanic support for 
tissues and when dysregulated, can leave increased inert lipid droplets (14). 
Excess inert lipid droplets in circulation exacerbate IR and inflammation within 
the cell (9). 
Lipocalin 2 (Lcn2), also known as neutrophil gelatinase-associated 
lipocalin (NAGL), is a 25 kDa adipose-derived cytokine expressed in adipose 
tissue, belonging to a lipocalin subfamily that binds retinoids, fatty acids, and 
steroids (1-3,5,34-38,40). The structure of Lcn2 is similar to that for retinol binding 
proteins and fatty acid binding proteins, and contains binding sites for nuclear 
factor- kB (NFkB) and CCAAT/enhancer-binding protein (C/EBP), as well as 
glucocorticoid responsive element within the promoter region (2,5).  
Research shows that there is a positive correlation between circulating 
Lcn2 levels and percentage of body fat percentage, blood pressure levels, insulin 
resistance, and altered lipid panels (37,38). In our previous studies, Lcn2 is shown 
to play a role in adipose tissue remodeling, inflammation, and adipocyte 
dysfunction (1,2,5). We also found that TGF- β expression in adipose tissue was 
dysregulated in Lcn2 KO mice (2), suggesting a potential link between Lcn2 and 
TGF- β in terms of their function in adipose tissue remodeling.  
Due to the qualities that both adipokines possess the role in extracellular 
matrix remodeling and inflammation, looking into the TGF- β effect on the 
regulation of ECM and inflammatory cytokines in Lcn2 deficient adipocytes may 
provide insight on these processes. Since this relationship has not been studied 
in adipose tissue, it is necessary to acquire more information about the function 
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of Lcn2 under inflammatory stimuli and the association with metabolic diseases is 
needed.  
We hypothesize that Lcn2 deficiency leads to dysregulated extracellular 
matrix remodeling and altered pro-inflammatory and anti-inflammatory cytokine 
responses via modulating the action of TGF- β. Therefore, our objectives are to 
determine how Lcn2 regulates the effect of TGF- β on inflammation and 
extracellular matrix remodeling in inguinal adipocytes. We performed the 
experiments to address how Lcn2 KO influences the response of adipocytes to 
TGF- β in the production of pro-inflammatory and anti-inflammatory cytokines 
and ECM proteins.  
Our results demonstrate that TGF- β down-regulates Lcn2 expression at 
both the mRNA and protein levels in inguinal adipocytes. Lcn2 KO adipocytes 
have lower levels of TGF- β expression, but normal levels of ribosomal protein 
S6 kinase (p70S6K) phosphorylation and normal response to TGF- β stimulation 
in mTORC1 signaling activation. However, the inhibitory effect of rapamycin on 
TGF- β expression is attenuated in Lcn2 KO adipocytes. Moreover, Lcn2 KO 
impairs the rapamycin potentiation of TGF- β effect on the expression of ECM 
proteins, but shows little effect on dysregulation of cytokines.   
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II. Results 
Lcn2 expression in inguinal adipocytes is regulated by TGF- β 
It is known that the presence of Lcn2 in white adipose tissue (WAT) 
is depot- specific, as well as gender-, and age dependent (5). Previous 
research indicates that there is an ample amount of Lcn2 in inguinal WAT 
in mice fed either a high-fat diet or regular chow; in these studies, protein 
expression and messenger Ribonucleic Acid (mRNA) expression of Lcn2 
was more abundant in the inguinal WAT versus the epididymal WAT (1,3). 
Due to the depot-specific response, we examined the effect of TGF- β on 
Lcn2 gene expression and protein expression in inguinal stromal vascular 
(SV) adipocytes. SV cells of wild type (WT) and Lcn2 KO mice were 
isolated from inguinal adipose tissue and cultured in vitro. Differentiation 
was induced and matured adipocytes were treated with TGF- β. In 
response to 10 ng/mL TGF-β treatment for 24 hours, mRNA expression of 
Lcn2 decreased significantly (p<0.0005), as shown in Figure 1A. 
Consistent with the mRNA expression, protein expression of Lcn2, when 
treated with TGF- β, rapamycin, or both, showed a decrease in expression 
from the basal condition (Figure 1B). Protein levels of Lcn2 in wild type 
(WT) adipocytes were increased, interestingly, when treated with 10 
ng/mL TGF- β for 1 hour versus the control, but when treated for 24 hours, 
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protein expression decreased in the TGF- β group versus the control, 
which is consistent with the mRNA expression (Figure 1C). Figure 1D 
indicates that TGF- β also has an impact on Lcn2 secretion in WT 
adipocytes. Lcn2 secretion was decreased in the 1 hour, 4 hour, and 24 
hour treatment groups versus the WT control. These results indicate that 
Lcn2 expression in inguinal adipocytes is regulated by TGF- β in a time-
dependent manner.  
 
TGF- β expression is decreased, but TGF- β action on mTOR 
signaling activation is unaffected in Lcn2 KO inguinal adipocytes. 
In our previous research, we have shown that mRNA levels of TGF- β 
were decreased more in the Lcn2 knock out (KO) mice fed a high-fat diet 
than in the WT mice (2). Figure 2A shows our results of mRNA expression 
in inguinal SV differentiated adipocytes support these findings showing 
decreased levels in the Lcn2 KO versus the WT adipocytes (p<0.01). 
However, when treated with 10 ng/mL TGF- β for 15, 30, and 60 minutes, 
WT and Lcn2 KO adipocytes similarly display a time-dependent increase 
in the phosphorylation of p70S6K, indicating that Lcn2 adipocytes have a 
normal response to TGF- β in mTOR signaling activation (Figure 2B). This 
suggests that the TGF- β effect on mTOR signaling activation is not 
impaired, although TGF- β expression is decreased in Lcn2 KO inguinal 
adipocytes.  
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Previous research indicated that cyclooxygenase-2 (COX-2) 
expression is upregulated by cytokines, such as TGF- β (23), and is the 
rate-limiting enzyme that increases prostaglandin (PG) synthesis, such as 
prostaglandin E2 (PGE2). PGE2 activates a G-coupled protein that 
activates the PI3K/AKT/mTOR signaling pathway (24). Therefore, we also 
looked at protein expression of COX-2 to determine the TGF- β effect on 
the activation of the PI3K/AKT/mTOR signaling pathway. Interestingly, we 
found that COX-2 protein levels were higher in Lcn2 KO adipocytes than 
in WT adipocytes under the basal condition (Figure 3A). When treated 
with TGF- β for 1, 4 and 24 hours in WT and Lcn2 KO adipocytes, Figure 
3A showed that that TGF- β treatment exacerbates the time-dependent 
upregulation of COX-2 seen in both WT and Lcn2 KO adipocytes, as the 
most significant upregulation in protein expression was seen after 24 
hours with TGF- β treatment. Moreover, TGF- β had a more significant 
effect on upregulation of COX-2 in Lcn2 KO adipocytes than the WT 
adipocytes at the 24-hour time point (Figure 3A). These results indicate 
the TGF- β upregulation of the COX-2 protein expression after 24 hours 
correlated with the activation of the mTOR signaling pathway. These 
results also suggest that Lcn2 deficiency does not affect TGF- β action on 
COX-2 expression and mTOR signaling activation.  
As indicated by other research in human carcinoma cells, rapamycin 
potentiates the effect of TGF- β in a dose-dependent manner (30). 
Rapamycin is a known mTOR inhibitor, especially with regards to 
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mTORC1 signaling. Activation of mTOR is evidenced by phosphorylation 
of downstream targets such as p70S6K (25). To determine how Lcn2 
deficiency affects rapamycin regulation of TGF- β expression in SV 
differentiated inguinal adipocytes, we assessed the mRNA expression 
levels of TGF- β in both WT and Lcn2 KO adipocytes when treated with 25 
nM rapamycin for 24 hours. When evaluating the mRNA expression in WT 
adipocytes, rapamycin significantly inhibits TGF- β expression (p<0.05), 
however in Lcn2 KO adipocytes the inhibitory effect of rapamycin is 
disrupted, as evidenced by a significant increase in TGF- β when treated 
with rapamycin (p<0.05) (Figure 2A).  
To determine the impact of Lcn2 deficiency on the effect of rapamycin, 
we detected the protein levels of p70S6K phosphorylation. Mature 
adipocytes were collected after 1 hour and 24 hours of treatment with 
TGF- β and rapamycin. Figure 3B shows that rapamycin blocks the 
phosphorylation of p70S6K in both WT and Lcn2 KO adipocytes in the 
presence or absence of TGF- β, with a more significant decrease in the 
Lcn2 KO adipocytes, especially after 1 hour of treatment with TGF- β 
compared to 24 hour treatment, whereas total S6K remained consistent 
(Figure 3B). Treatment with TGF- β alone led to the upregulation of 
p70S6K in both WT and Lcn2 KO adipocytes, although phosphorylation of 
S6K is greater in the Lcn2 KO adipocytes than the WT after 1 hour. The 
data indicates that Lcn2 deficiency does not influence the inhibitory effect 
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of rapamycin on mTOR signaling by evidence of reduced phosphorylation 
of p70S6K in both WT and Lcn2 KO adipocytes at a similar level.  
 
 
 
The effect of TGF- β and rapamycin on inflammation in Lcn2 KO 
adipocytes  
The above results indicate that rapamycin has an inhibitory effect 
on TGF- β evidenced by decreased expression of TGF- β when 
adipocytes were treated with rapamycin versus the control. Research 
indicated that TGF- β and mTOR signaling interact, which is inhibited by 
rapamycin, and rapamycin enhances the action of TGF- β (24,25,29,40). 
Since increased mTORC signaling, which is associated with “pro-growth” 
signals causes dysregulation of the ECM remodeling and inflammatory 
cytokines (25), it is imperative to determine if Lcn2 deficiency alters the 
effect of TGF- β and rapamycin on pro- and anti-inflammatory cytokines 
(1). Therefore, we determined the regulation of pro-inflammatory cytokines 
such as Interleukin-6 (IL-6), tumor necrosis factor α (TNFα), and Monocyte 
Chemoattractant Protein-1 (MCP1) in WT and Lcn2 KO adipocytes treated 
with TGF- β for 20 hours. With regards to the effect of TGF- β on the WT 
and Lcn2 control cells, Figure 4A shows there is a significant decrease in 
MCP1 in both groups (p<0.05, p<0.0001, respectively), but not in TNFα or 
IL-6. mTOR signaling was then blocked using rapamycin with TGF- β, 
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which resulted in similar results in that there was no significant effect of 
TGF- β in WT or Lcn2 KO cells for TNFα or IL-6 (Figure 4B and 4C, 
respectively), but there was a significant decrease in MCP1 (p<0.0001). 
There is not a significant difference between the WT and Lcn2 KO 
adipocytes in any of the pro-inflammatory cytokines, suggesting that Lcn2 
deficiency does not have a significant affect on the TGF- β effect on MCP-
1, TNFα or IL-6. There was, however, a significant increase (p<0.001) in 
IL-6 and MCP-1 expression as a result of rapamycin treatment 
independent of TGF- β in both WT and Lcn2 KO adipocytes (Figure 4A 
and 4C, respectively). Interestingly, we saw that IL-6 expression also 
increased more in the Lcn2 KO adipocytes compared to the WT 
adipocytes (p<0.05) in response to rapamycin. This implies that Lcn2 
impairs the rapamycin effect on gene expression of IL-6 (Figure 4C).  
We also determined the mRNA expression of M2 macrophage 
markers in adipocytes treated after differentiation for 20 hours with TGF- β 
alone or in combination with rapamycin. When looking at M2 macrophage 
markers, Macrophage mannose receptor 1 (MRC-1) and Arginase 1 
(Arg1), there is a significant decrease in mRNA expression in MRC-1 gene 
expression in Lcn2 KO and WT adipocytes when treated with TGF- β  
(p<0.005, p<0.05, respectively)(Figure 4D). Rapamycin either alone or in 
combination with TGF- β does not affect MRC-1 mRNA expression (Figure 
4D). There is also no difference in MRC-1 expression between WT and 
Lcn2 KO adipocytes in response to TGF- β and/or rapamycin. The mRNA 
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expression of Arginase 1 showed differential regulation of TGF- β as 
significant increases in WT adipocytes, but not in the Lcn2 KO adipocytes. 
The Lcn2 adipocytes, however, did show an increase in mRNA expression 
of Arg1 in response to the TGF- β, but it was not significant (Figure 4E). 
Furthermore, WT and Lcn2 KO adipocytes show a significantly different 
response to the treatment of TGF- β and rapamycin in combination. When 
treated with TGF- β and rapamycin together, the mRNA expression of 
Arg1 was significantly decreased in WT adipocytes (p<0.05), but 
increased in Lcn2 KO adipocytes (p<0.05) (Figure 4E).  This implies that 
Lcn2 does impair the effect of TGF- β and rapamycin on gene expression 
of Arg1.  
 
The effect of TGF- β and rapamycin on extracellular matrix in Lcn2 
KO adipocytes  
Because TGF- β is strongly associated with synthesis of ECM 
protein in most fibrogenic cells and is an important regulator of the fibrotic 
response (21,33), its relationship with Lcn2, which also has a know 
relationship with adipose tissue remodeling due to its ability to regulate 
high fat diet-induced adipogenic defect and inflammation (2,5) was of 
interest. Hence, we investigated the effect of TGF- β and rapamycin on 
ECM proteins in Lcn2 KO adipocytes. The mRNA expression of proteins 
supporting the ECM, Collagen 1A1 (Col1A1), Collagen 3A1 (Col3A1), and 
matrix metallopeptidase 9 (MMP9), were evaluated when treated with 
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TGF- β and rapamycin for 20 hours. With regards to the effect of TGF – β 
in both WT and Lcn2 KO adipocytes, there were significant decreases in 
Col3A1 and significant increase in MMP9 that were independent of Lcn2 
deficiency (p<0.0001); there was no significant change in Col1A1 gene 
expression compared to the controls (Figure 5A, 5B and 5C, respectively).  
When mTOR signaling was blocked with rapamycin, a significant 
difference in the effect of TGF- β between WT and Lcn2 KO adipocytes 
were seen for both MMP9 (Figure 5B) and Col1A1 (Figure 5C) (p<0.005). 
While rapamycin significantly augmented the stimulatory effect of TGF- β 
on MMP9 and Col1A1 expression in WT adipocytes, rapamycin has much 
less of an effect in Lcn2 KO adipocytes. This suggests that Lcn2 
deficiency impairs TGF- β and mTOR signaling interaction. However, 
there were no significant changes in mRNA expression of Col3A1 (Figure 
5A). There was a decreased response in the Lnc2 KO adipocytes versus 
the WT adipocytes when treated with both TGF- β and rapamycin, as well 
as a significant increase in mRNA expression of Col3A1as a result of 
rapamycin treatment alone in the Lcn2 KO adipocytes compared to the 
WT adipocytes (p<0.05) as shown in Figure 5A.  
When treated with 10 ng/mL TGF- β for 1, 4 and 24 hours in WT 
adipocytes and 24 hours in Lcn2 KO adipocytes, MMP9 protein 
expression displayed abnormal results as seen in Figure 5D. TGF- β 
significantly upregulated protein expression of MMP9 in WT adipocytes 
treated for 1 and 4 hours, as well as Lcn2 KO adipocytes treated for 24 
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hours. However, WT adipocytes treated with TGF- β for 24 hours showed 
a significant decrease in protein expression of MMP9 versus the control. 
These results contradict the MMP9 mRNA expression seen in Figure 5B 
which displays a 4.7-fold increase from the basal conditions in both WT 
and Lcn2 KO adipocytes when treated with TGF- β alone, and when 
treated with TGF- β and rapamycin, an 8.8-fold increase in Lcn2 KO 
adipocytes and 10.8-fold increase in WT adipocytes. We hypothesize that 
decreased MMP9 protein levels could be due to a feedback mechanism 
that decreases mRNA expression once MMP9 transcription has been 
significantly upregulated, thus giving opposite results in protein expression 
and mRNA expression. However, MMP9 protein levels were markedly 
upregulated by TGF- β treatment for 20 hours in Lcn2 KO adipocytes 
(Figure 5D).  
From these experiments, we concluded that Lcn2 deficiency does 
not significantly affect the TGF- β effect on gene expression of the ECM. 
Lcn2 deficiency, however, does impair the rapamycin effect on ECM 
proteins, particularly in the presence of TGF- β. Combined, these results 
suggest that mTOR signaling is involved in Lcn2 regulation of the TGF- β 
effect on ECM remodeling and cytokine production, but the exact 
mechanism is still unknown. 
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III. Discussion  
 TGF- β’s growing role in ECM remodeling in tissues and known 
relationship to activation of the mTOR signaling pathway has made this an 
inflammatory cytokine of interest (21,22,24,25). In our previous studies, dysregulation 
of TGF- β has been suggested to potentially contribute to impaired ECM 
remodeling in adipose tissue of Lcn2 KO mice. In this study, we further explored 
the role of TGF- β on Lcn2 expression in inguinal adipocytes to obtain a better 
understanding of the function of Lcn2. In WT adipocytes, where the presence of 
Lcn2 is abundant (2,3), we observed the effect of TGF- β treatment on mRNA 
levels of Lcn2; WT adipocytes treated with TGF- β for 24 hours showed a 
significant decrease in mRNA expression and protein expression compared to 
the control. This suggests that TGF- β regulates Lcn2 expression in inguinal 
adipocytes, although the exact mechanism is still unknown.  
 TGF- β is known to increase the expression of rate-limiting enzyme COX-2 
in various different cell types, which in turn activates the PI3K/AKT/mTOR 
signaling pathway (23,24), thus increasing mTOR signaling and phosphorylation of 
its downstream targets such as S6K (22,25). Our previous results show 
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significantly decreased mRNA levels of TGF- β in adipose tissue of Lcn2 KO 
mice fed a high-fat diet compared to the WT mice, indicating that Lcn2 has a role 
in expression of TGF- β (2). Our results in WT and Lcn2 KO adipocytes concur 
with previous findings showing a significant decrease in mRNA expression. 
However, when the WT and Lcn2 KO adipocytes were treated with TGF- β for a 
short time period (15-60 minutes), as well as a longer time-period (1hr-24hrs), 
normal phosphorylation of p70S6K was displayed, suggesting that although TGF- 
β expression is decreased, deficiency of Lcn2 in adipocytes does not have an 
effect on mTOR signaling activation. However, when WT and Lcn2 KO 
adipocytes were treated with TGF- β for 1, 4, and 24 hours, COX-2 protein 
expression did show a significant increase in the 24-hour treatment group, with a 
greater upregulation in the Lcn2 KO adipocytes than in the WT adipocytes. The 
COX-2 protein expression levels were higher in the Lcn2 KO adipocytes than in 
the WT adipocytes, even in the basal state. This upregulation in COX-2 
expression was also seen in prostate cancer cells (24) and human mesangial 
cells (23), suggesting increased activation of mTOR. However, in this study, 
upregulation of COX-2 expression does not correlate with an increase in 
phosphorylation of p70S6K, implying that COX-2 may not be the only pathway 
that mediates TGF- β activation of mTORC1. It is also possible that COX-2 is 
involved in the activation of mTORC2, which phosphorylates AKT on site Ser473 
(22). Increased upregulation of COX-2 in Lcn2 KO adipocytes versus the WT 
adipocytes indicates that Lcn2 may negatively regulate COX-2 expression.  
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 In fibroblasts, human target of rapamycin was found to inhibit the activity 
of mTORC1, and not mTORC2, when stimulated with TGF- β treatment (25). 
Another study found that the action of TGF- β alone or rapamycin alone had no 
significant effect on Mv1Lu transformed cells, but when treating the cells with 
both TGF- β and rapamycin together, there was a significant, dose-dependent 
effect on cell proliferation (30), suggesting an interaction between TGF- β and 
mTOR signaling pathways. We then investigated if this pathway interaction is 
affected in Lcn2 adipocytes. First, we studied the impact of Lcn2 deficiency on 
the rapamycin effect of TGF- β. We found that rapamycin significantly decreases 
the mRNA expression of TGF- β in the WT adipocytes, but significantly increases 
mRNA expression of TGF- β in the Lcn2 KO adipocytes. Moreover, treatments 
with rapamycin, or both TGF- β and rapamycin for 1 hour led to a significant 
decrease in phosphorylation of p70S6K in both WT and Lcn2 KO adipocytes 
when treated with rapamycin or both TGF- β and rapamycin, with a slightly more 
significant decrease seen in Lcn2 adipocytes than the WT. After 24 hours of 
treatment with TGF- β and rapamycin, p70S6K phosphorylation was significantly 
decreased in Lcn2 KO adipocytes compared to WT adipocytes in the basal and 
TGF- β treated states. Rapamycin or rapamycin plus TGF- β completely blocks 
p70S6K phosphorylation in both WT and lcn2 KO adipocytes. There was no 
significant difference in the effect of rapamycin and TGF- β treatment on mTOR 
signaling activation between the WT and Lcn2 KO adipocytes after 24 hours. 
Therefore, these results indicate that Lcn2 does not affect the inhibitory effect of 
rapamycin on mTOR signaling.  
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 Although there was no difference between WT and Lcn2 KO adipocytes 
with regards to the effect of rapamycin inhibiting mTOR signaling when treated 
with TGF- β, rapamycin did have a significant inhibitory effect on mTOR signaling 
when treated with TGF- β in adipocytes. Other research has demonstrated the 
inhibitory effect of rapamycin in cancer cells (24,29,30) and fibroblasts (25), and has 
found a relationship between increased mTOR signaling and dysregulation of 
inflammatory cytokines (25,26) and ECM remodeling (25). Thus, identifying the 
relationship between TGF- β treatment and inflammation in WT and Lcn2 KO 
adipocytes is of interest. When treated with TGF- β, the chemokine responsible 
for macrophage infiltration, MCP1, showed a significant decrease in mRNA 
expression. The effect of TGF- β was not exacerbated when treated together with 
rapamycin, although there was a significant increase when treated with only 
rapamycin. There was however, no difference in the response between WT and 
Lcn2 KO adipocytes. In pro-inflammatory cytokines, TGF- β treatment alone or 
with rapamycin had no significant effect on mRNA expression of TNFα and IL-6 
and no difference between the WT and Lcn2 KO adipocytes. Because there was 
no significant difference between the WT and Lcn2 KO adipocytes, we conclude 
that Lcn2 does not have an effect on the TGF- β- mediated inflammatory 
response in adipocytes. Rapamycin, however, independent of TGF- β may have 
a significant effect on inflammatory cytokines with regards to its significant 
increase in both MCP-1 and IL-6 gene expression, especially in IL-6, where a 
significant difference was seen between the increase in WT and Lcn2 KO 
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adipocytes. This suggests that Lcn2 deficiency impairs the rapamycin effect on 
gene expression with regards to cytokine IL-6.  
 Next we examined the effect of TGF- β on M2 macrophage markers, Arg1 
and MRC-1 in Lcn2 KO adipocytes.  The mRNA expression in Arg1 and MRC-1 
were significantly increased and significantly decreased, respectively, with a 
more profound increase in the WT adipocytes than the Lcn2 KO adipocytes in 
Arg1 expression. When mTOR signaling was blocked using rapamycin with the 
TGF- β treatment, there was a significantly different response in Arg1 expression 
between WT and Lcn2 KO adipocytes. For instance, blocking mTOR signaling 
activation leads to a significant decrease in TGF- β induction of Arg1 expression 
in WT adipocytes, but an increase in Lcn2 KO adipocytes. This notably 
significant difference in response between the WT and Lcn2 KO adipocytes when 
treated with TGF- β and rapamycin implying that Lcn2 deficiency impairs the 
effect of rapamycin and TGF- β interaction on gene expression of macrophage 
marker, Arg1.  
 Lcn2 KO adipocytes were found to have increased mRNA expression 
levels of collagens and fibronectin compared to WT type adipocytes (2) with a 
suspected role of TGF- β in controlling local concentrations of ECM proteins (21).  
Suggesting that Lcn2 has a role in ECM remodeling due to decreased TGF- β 
levels in inguinal adipocytes displaying increased hypertrophy and depot 
expansion (2), the effect of TGF- β and rapamycin on ECM in WT and Lcn2 
adipocytes is of interest. Therefore, we researched the mRNA expression in 
ECM proteins Col1A1, Col3A1, and MMP9 after treatment with TGF- β, 
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rapamycin, and TGF- β and rapamycin. Collagen proteins Col1A1 and Col3A1 
showed opposite results of each other with regards to gene expression when 
treated with TGF- β for 24 hours. Significant decreases in Col3A1 and no 
significant change in Col1A1 with TGF- β treatment led us to investigate the 
effect of rapamycin. When treated with TGF- β and rapamycin, Col1A1 showed a 
significant increase in gene expression, in WT, but not Lcn2 adipocytes, whereas 
Col3A1 showed a significant decrease in gene expression when treated with 
TGF- β and rapamycin with a significant difference between the WT and Lcn2 KO 
adipocytes; in both collagen proteins, the WT adipocytes displayed significantly 
higher gene expression than the Lcn2 KO adipocytes. This suggests that Lcn2 
plays a role in regulating the interaction between mTOR and TGF- β signaling 
pathways in terms of their effect on ECM protein expression.  
Of note, MMP9 showed a significant increase in mRNA expression with 
TGF- β treatment and further increase as a result of TGF- β treatment blocked 
with rapamycin. Moreover, there was a significant difference between the WT 
and Lcn2 KO adipocytes, with a lesser increase in Lcn2 KO adipocytes. This 
suggests that Lcn2 deficiency impairs TGF- β and mTOR signaling interaction 
with regards to MMP9 mRNA expression. However, the effect of TGF β and 
rapamycin on MMP9 protein expression contradicts the gene expression. When 
treated with TGF- β, there was a time-dependent increase in MMP9 protein 
expression for WT adipocytes at 1 and 4 hours, but a decrease in expression at 
24 hours. For the Lcn2KO adipocytes treated with TGF- β for 24 hours, there 
was, however, an increase in protein expression of MMP9 expression. This 
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suggests that there may be a feedback mechanism regulating the protein 
expression of MMP9, controlled by gene expression. Therefore, we concluded 
that Lcn2 deficiency does not significantly affect the TGF- β effect on gene 
expression of the ECM protein such as Col1A1, Col3A1, and MMP9, but does 
interfere with rapamycin potentiation of the TGF- β effect. These results, 
however, do indicate that mTOR signaling is involved in Lcn2 regulation of the 
TGF- β effect on ECM remodeling.  
In conclusion, this research has demonstrated that TGF- β down-regulates 
Lcn2 expression at both the mRNA and protein expression levels in inguinal 
adipocytes. Furthermore, Lcn2 KO adipocytes have lower levels of TGF- β 
expression, but normal levels of S6K phosphorylation and normal response to 
TGF- β stimulation in mTORC1 signaling activation. Research has also shown 
the exacerbated effect of TGF- β when mTOR signaling is blocked by rapamycin; 
however, we have shown that the inhibitory effect of rapamycin on TGF- β 
expression is attenuated in Lcn2 KO adipocytes, specifically. Moreover, Lcn2 KO 
impairs the rapamycin potentiation of TGF- β effect on the expression of ECM 
proteins, but shows little effect on dysregulation of cytokines.  Other studies have 
shown that Lcn2 deficiency increases ECM remodeling and fibrosis in adipose 
tissue, with a more profound response in inguinal adipose tissue with regards to 
adipocyte hypertrophy when mice were fed a high-fat diet. Combined, our results 
indicate that Lcn2 plays a role in the inhibitory effect of rapamycin on TGF- β 
expression and mTOR signaling activation.  
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In future research, investigating complex-specific mTOR signaling in 
response to TGF- β and rapamycin would be of interest to see if there is a 
relationship to specific signaling pathways with regards to ECM remodeling and 
inflammatory cytokine dysregulation. It would also be beneficial to conduct similar 
research, using TGF- β in whole tissue or whole-body relations to systemic, low-
grade inflammation to see if there is a different response when other organs are 
involved; on a larger spectrum, research investigating the application to human 
obesity and chronic inflammation, and how the TGF- β and mTOR signaling 
pathway could be manipulated to reduce systemic low-grade inflammation and 
ECM remodeling. Lastly, further research would be needed to investigate the 
detailed mechanism of how Lcn2 affects the mTOR signaling pathway to 
influence the ECM and inflammation.  
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IV. Materials and Methods  
a. Animal studies  
C57BL/6 WT and Lcn2 KO mice provided by Dr. Alan Aderem 
(Institute for Systems Biology, Seattle, Washington), which were 
originally generated by Dr. Shizuo Akira (Research Institute for 
Microbial Diseases, Osaka University, Osaka, Japan, were used in 
this study. Through gene targeting the Lcn2 KO mice were 
generated in embryonic stem cells from the mouse strain 129, and 
the targeted embryonic stem cells were injected into C57BL/6 
blastocysts (35) as described in research done by Flo, et al. 
C57BL/6 mice were purchased form the Jackson Laboratory (Bar 
Harbor, ME). Before the mice were used for experiments, the Lcn2-
null mice were backcrossed onto the B6 background for 10 
generations. A heterozygous mating scheme was used to generate 
WT and Lcn2 KO mice for the experiments.  
	   48	  
Animals were housed in a specific pathogen-free facility at 
the University of Minnesota. Animal handling followed the National 
Institutes of Health guidelines, and experimental procedures were 
approved by the University of Minnesota Animal Care and Use 
Committee. The mice were allocated into groups (3-4 mice per 
cage) and fed a regular chow diet, with free access to water in all 
studies. At 14 weeks of age, the mice were killed and adipose 
tissues were collected for the isolation of stromal-vascular (SV) 
cells.   
b. Isolation of primary adipocytes and SV cells 
 Primary adipocytes and SV cells were isolated from WT and 
Lcn2 KO mice. After mincing, inguinal fat pads were digested with 
collagenase (2 mg/mL solution) in digestion vials containing Krebs-
Ringer bicarbonate HEPES buffer (pH 7.4), 200 nM adenosine, and 
3.5% BSA. After a 2-hour digestion, adipocytes and SV cells were 
separated by centrifugation at 1200 rpm for 10 minutes and washed 
twice with Krebs-Ringer bicarbonate HEPES buffer. After the final 
wash, SV cells were collected and cultured.  
 
c. Cell Culture  
SV cells isolated from inguinal adipose tissue of WT and 
Lcn2 KO mice were cultured in DMEM with 10% bovine calf serum 
(Sigma Aldrich, Saint Louis, MO) and 100 IU/mL 
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penicillin/streptomycin (Invitrogen, Carlsbad, CA) until confluent. 
Two days after confluence, the cells were induced for differentiation 
with using a differentiation cocktail containing 10% fetal bovine 
serum (Sigma Aldrich, Saint Louis, MO), and 390 ng/mL 
dexamethasone (Sigma Aldrich, Saint Louis, MO). The 
differentiation cocktail was replaced by 10% fetal bovine serum, 
100 IU/mL penicillin/streptomycin and 1 ug/mL insulin after two 
days. The cells were cultured for six days following. On day 7 of 
differentiation, the adipocytes were starved in DMEM with 1 mg/mL 
glucose and 0.5% bovine calf serum for 4 hours, then treated with 
10 µg/mL insulin and 10 ng/mL TGF-β (R & D System, Minneapolis, 
MN), 25 nM rapamycin, or both treatments for various amounts of 
time as noted in the figure legends. Both conditioned media and 
cells were collected for protein or mRNA detection.  
 
d. RNA Extraction for Quantitative real-time RT-PCR 
Total RNA was extracted from adipocytes using TRIzol 
reagent (Intvitrogen, Carlsbad, CA) according to manufacturer’s 
instructions. After treatment with RQ1 DNase (Promega, Madison, 
WI), 1 µg RNA was used to synthesize the cDNA in reverse 
transcription with 5 mM oligo dT primer, 0.5 uM dNTP, 20 units 
RNasin Ribonuclease Inhibitor (Promega, Madison, WI), 5 mM 
DTT, and 100 units SuperScript II Reverse Transcriptase 
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(Intvitrogen, Carlsbad, CA). Teal-time-PCR was performed using 
SYBR GreenER qPCR SuperMix Universal kit (Intvitrogen, 
Carlsbad, CA) with an ABI 7500 Real Time PCR System (Applied 
Biosystems, Foster City, CA). Results were analyzed using the 
software supplied with the 7500 system and presented as levels of 
expression relative to that of controls after normalizing to TBP-2 
using the ΔΔCt method (3).  
e. Protein Preparation for Western Blotting  
Adipocytes were solubilized in a lysis buffer containing 25 
nM Tris-HCl pH 7.5, 0.5 mM EDTA, and 25 mM sodium chloride, 10 
mM sodium fluoride, 1 mM sodium vanadate, 1% Nonidet P-40 and 
protease inhibitor cocktails (Diagnostic Roche, Branchburg, NJ). 
The lysates were centrifuged at 12,000 g for 10 minutes, and 
supernatants were collected. Protein concentrations of lysates were 
detected with bicinchoninic acid method (Pierce, Rockford, IL). 
Equivalent proteins or same volume of conditioned media were 
loaded and separated on SDS-PAGE and then electro-transferred 
to nitrocellulose membranes. Membranes were incubated with anti-
Lcn2 (R&D System, Minneapolis, MN), anti- MMP9 (R & D System, 
Minneapolis, MN), anti-p70S6K (Cell Signaling Technology, 
Danvers, MA), and anti-actin (Cell Signaling Technology, Danvers, 
MA) antibodies after blocking with TTBS (20 nM Tris-HCl pH 7.5, 
0.5 M NaCl, 0.1% Tween-20) containing 5% skim milk (Fisher 
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Scientific, Pittsburgh, PA). The membranes were then washed in 
TTBS and incubated with corresponding secondary antibodies 
conjugated to horseradish peroxidase (GE Healthcare Bio-Sciences 
Corp., Piscataway, NJ). The signals were detected by ECL plus 
Western Blotting Detecting Reagents (GE Healthcare Bio-Sciences 
Corp., Piscataway, NJ) (3).  
 
f. Statistical analysis 
The results are expressed as mean ± SEM. Differences in 
parameters between WT and Lcn2 KO adipocytes were evaluated 
using a two-group t test with a 0.05 two-sided significance level. 
Significance was considered a P value <0.05.  
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APPENDICES 
 
 
Figure 1. A shows the mRNA expression of Lcn2 in WT adipocytes when 
treated with TGF- β, rapamycin, and TGF- β + rapamycin for 20 hours. Results 
indicate mean ± SE. #, p < 0.05 from WT control. B and C, Lcn2 protein 
expression in WT adipocytes treated with TGF- β, rapamycin, or TGF- β and 
rapamycin for time periods as noted. D, Lcn2 secretion in WT and Lcn2 KO 
adipocytes when treated with TGF- β for 1, 4, or 24 hours.  
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Figure 2. A, the mRNA expression of TGF- β in WT and Lcn2 KO adipocytes 
when treated with rapamycin for 20 hours. Results indicate mean ± SE. #, p < 
0.05 from WT control; *, p < 0.05, WT vs. Lcn2 KO.  B, p70S6K protein 
expression in WT and Lcn2 KO adipocytes when treated with TGF- β for 
15,30, 60 minutes.  
Figure 3. A, protein expression of COX-2 in WT and Lcn2 KO adipocytes when 
treated with TGF- β for 1, 4, or 24 hours. B, protein expression of p70S6k and 
total S6K in WT and Lcn2 KO adipocytes treated with TGF- β, rapamycin, or 
TGF- β and rapamycin for 1, 4, and 24 hours.  
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Figure 4. A-E, the mRNA expression of MCP-1 (A), TNFα (B), IL-6 (C), 
MRC-1 (D), Arg1 (E) in WT and Lcn2 KO adipocytes, when treated with 
TGF- β, rapamycin, or TGF- β and rapamycin for 20 hours. Results 
indicate mean ± SE. #, p < 0.05; ##, p < 0.005 from WT control; *, p < 0.05; 
**, p , 0.005, WT vs. Lcn2 KO.    	  
	   64	  
 
 
 
 
 
 
 
 
Figure 5. A-C, the mRNA expression of Col3A1 (A), MMP9 (B), Col1A1 (C) in 
WT and Lcn2 KO adipocytes when treated with TGF- β, rapamycin, or TGF- β 
and rapamycin for 20 hours. Results indicate mean ± SE. #, p < 0.05; ##, p < 
0.005 from WT control; *, p < 0.05; **, p , 0.005, WT vs. Lcn2 KO.  D, protein 
expression of MMP9 expression in WT and Lcn2 KO adipocytes treated with 
TGF- β for time periods as noted.  
